mannkind corporation danbury, ct addresswhy was matt houston cancelled

MannKind Corporation. Start of main content. Where is MannKind located? All Jobs 1 Casper St Danbury CT 06810. Find company research, competitor information, contact details & financial data for Mannkind Corporation of Danbury, CT. Get the latest business insights from Dun & Bradstreet. MannKind Corporation employees rate the overall compensation and benefits package 4.0/5 stars. Committed to diversity, at MannKind we depend on a rich blend of ideas . 1 Casper St Danbury, CT 06810-6903 VIEW MAP (203) 207-0912 www.mannkindcorp.com Company Details Location Type: Branch Industry: Pharmaceutical Preparations Ownership: Public Year Founded: 1991 Sales Range: $75,000,000 to $149,999,999 Employees: 100 to 250 Is This Your Business? Find jobs. ","language":"en","releaseDate":{"dateUTC":"2020-02-20T14:00:00","date":"2020-02-20T09:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Presents Novel Scientific Data at 13th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2020)","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16941/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/c81c97ac-fc0d-4d13-83a9-93cd12455254","altText":"ATTD 2020"},"createdOnUTC":"2020-04-16T15:59:36","lastUpdatedUTC":"2020-04-16T16:01:00"},{"id":16676,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16676","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/afrezzar-insulin-human-inhalation-powder-receives-pricing"},"title":"Afrezza (insulin human) Inhalation Powder Receives Pricing Registration in Brazil Commercial activities to commence this month","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Jan. 06, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) announced today that its Brazilian partner, Biomm S.A. , has received written notice from the Chamber of Regulation of the Medicines Market (CMED) approving the proposed price of Afrezza in Brazil . Easily apply. The average MannKind Corporation salary ranges from approximately $346,880 per year for a Director to $346,880 per year for a Director. At MannKind our employees are our number one asset, and we continue becoming a tight-knit community where each of us plays a critical role in our collective success. Browse 19 jobs at MannKind Corporation near Danbury, CT. ","language":"en","releaseDate":{"dateUTC":"2020-11-30T13:00:00","date":"2020-11-30T08:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Sabrina Kay Appointed to MannKind Board of Directors","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17261/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-11-30T13:02:46","lastUpdatedUTC":"2020-11-30T13:02:46"},{"id":17256,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17256","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-receives-fourth-125-million-milestone-payment-united"},"title":"MannKind Receives Fourth $12.5 Million Milestone Payment from United Therapeutics","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Nov. 19, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that it has achieved the final development milestone under its licensing and collaboration agreement with United Therapeutics for the development and commercialization of a dry powder","language":"en","releaseDate":{"dateUTC":"2020-11-19T22:00:00","date":"2020-11-19T17:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Receives Fourth $12.5 Million Milestone Payment from United Therapeutics","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17256/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-11-19T22:01:18","lastUpdatedUTC":"2020-11-19T22:01:18"},{"id":17241,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17241","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2020-third-quarter-financial"},"title":"MannKind Corporation Reports 2020 Third Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 PM ET 3Q 2020 U.S. Afrezza Net Revenue of $7.3 million ; +27% vs. 3Q 2019 3Q YTD 2020 U.S. Afrezza Net Revenue of $22.1 million ; +31% vs. 3Q YTD 2019 Cash and cash equivalents of $52.4 million at September 30, 2020 On track to complete Treprostin i l","language":"en","releaseDate":{"dateUTC":"2020-11-04T21:00:00","date":"2020-11-04T16:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2020 Third Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17241/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-11-04T21:00:54","lastUpdatedUTC":"2020-11-04T21:00:54"},{"id":17221,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17221","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2020-third-quarter-financial-results"},"title":"MannKind Corporation to Hold 2020 Third Quarter Financial Results Conference Call on November 4, 2020","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Oct. 29, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 third quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday,","language":"en","releaseDate":{"dateUTC":"2020-10-29T12:00:00","date":"2020-10-29T08:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2020 Third Quarter Financial Results Conference Call on November 4, 2020","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17221/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-10-29T12:03:08","lastUpdatedUTC":"2020-10-29T12:03:08"},{"id":17216,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17216","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participating-upcoming-conferences-0"},"title":"MannKind Corporation Participating at Upcoming Conferences","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Sept. 08, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with diabetes and orphan lung diseases, announced today that it will be participating at","language":"en","releaseDate":{"dateUTC":"2020-09-08T12:00:00","date":"2020-09-08T08:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Participating at Upcoming Conferences","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17216/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-09-08T12:02:05","lastUpdatedUTC":"2020-09-08T12:02:05"},{"id":17166,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17166","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/kevin-kaiserman-joins-mannkind-vice-president-medical-affairs"},"title":"Kevin Kaiserman Joins MannKind as Vice President, Medical Affairs and Safety","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Aug. 31, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced that Kevin Kaiserman , MD, has joined the company as Vice President, Medical Affairs and Safety and will assume full responsibility for leading MannKinds medical affairs, field medical","language":"en","releaseDate":{"dateUTC":"2020-08-31T13:00:00","date":"2020-08-31T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Kevin Kaiserman Joins MannKind as Vice President, Medical Affairs and Safety","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17166/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/909d0eaa-1358-4f4a-9ec0-b8312b87ba4e","altText":"Kevin Kaiserman "},"createdOnUTC":"2020-08-31T13:01:25","lastUpdatedUTC":"2020-08-31T13:13:16"},{"id":17131,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17131","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-btig-virtual-biotechnology"},"title":"MannKind Corporation to Participate in BTIG Virtual Biotechnology Conference 2020","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Aug. 07, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with diabetes and orphan lung diseases, announced today that its Chief Executive Officer,","language":"en","releaseDate":{"dateUTC":"2020-08-07T21:00:00","date":"2020-08-07T17:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in BTIG Virtual Biotechnology Conference 2020","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17131/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-08-07T21:00:41","lastUpdatedUTC":"2020-08-07T21:00:41"},{"id":17116,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17116","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2020-second-quarter-financial"},"title":"MannKind Corporation Reports 2020 Second Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 PM ET 2Q 2020 Afrezza Net Revenue of $7.0 million ; +15% vs. 2Q 2019 1H 2020 Afrezza Net Revenue of $15.0 million ; +35% vs. 1H 2019 Cash and cash equivalents of $63.2 million at June 30, 2020 Non-GAAP cash used in operating activities decreased by 37% vs.","language":"en","releaseDate":{"dateUTC":"2020-08-05T20:00:00","date":"2020-08-05T16:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2020 Second Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17116/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-08-05T20:00:48","lastUpdatedUTC":"2020-08-05T20:00:48"},{"id":17091,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17091","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2020-second-quarter-financial-results"},"title":"MannKind Corporation to Hold 2020 Second Quarter Financial Results Conference Call on August 5, 2020","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , July 29, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 second quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, August","language":"en","releaseDate":{"dateUTC":"2020-07-29T21:00:00","date":"2020-07-29T17:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2020 Second Quarter Financial Results Conference Call on August 5, 2020","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17091/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-07-29T21:00:49","lastUpdatedUTC":"2020-07-29T21:00:49"},{"id":17086,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17086","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/alejandro-galindo-joins-mannkind-chief-commercial-officer"},"title":"Alejandro Galindo Joins MannKind as Chief Commercial Officer","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , July 20, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced that effective August 4, 2020 , Alejandro Galindo , M.B.A, M.S., will be leading MannKinds commercial operations as Chief Commercial Officer. Director/Executive Director, Pharmaceutical Process Technology. Committed to diversity, at MannKind we depend on a rich blend of ideas, backgrounds, and working styles in our quest to change the world for the better. 2023 MannKind Corporation. Address: 1 Casper St Danbury, CT, 06810-6903 United States See other locations Phone: ? Corporate Governance. Computershare: Mailing Address P.O. Associate Director, CMC Product Lead. United Therapeutics Tyvaso DPI represents the second FDA-approved product utilizing MannKinds innovative Technosphere inhalation technology. All rights reserved. Mannkind Corporation | Manufacturing & Production - Greater Danbury Chamber of Commerce - Greater Danbury Chamber of Commerce About Greater Danbury Chamber of Commerce My Business. Company reviews. ","language":"en","releaseDate":{"dateUTC":"2020-06-15T13:00:00","date":"2020-06-15T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Presents Positive Original Analyses of Afrezza Clinical Data at American Diabetes Association (ADA) 80th Scientific Sessions","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17051/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-06-15T13:01:30","lastUpdatedUTC":"2020-06-15T13:01:30"},{"id":17046,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17046","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/investigator-initiated-study-shows-switching-afrezzar-improves"},"title":"Investigator-Initiated Study Shows Switching to Afrezza Improves Glucose Control with No Additional Hypoglycemia in T2DM","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , June 13, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced that data from a new clinical study of Afrezza (insulin human) Inhalation Powder will be presented at the American Diabetes Associations 80th Scientific Sessions during the ePoster session","language":"en","releaseDate":{"dateUTC":"2020-06-13T16:00:00","date":"2020-06-13T12:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Investigator-Initiated Study Shows Switching to Afrezza Improves Glucose Control with No Additional Hypoglycemia in T2DM","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17046/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-06-13T16:00:35","lastUpdatedUTC":"2020-06-13T16:00:35"},{"id":16976,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16976","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2020-first-quarter-financial"},"title":"MannKind Corporation Reports 2020 First Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 PM ET 1Q 2020 Afrezza Net Revenue of $8.0 million ; +58% vs. 1Q 2019 1Q 2020 Afrezza gross profit 48% vs. 21% in 1Q 2019 Non-GAAP Net Cash Used in Operating Activities in 1Q 2020 was $11.2 million ; a reduction of 53% vs. 1Q 2019 WESTLAKE VILLAGE, Calif.","language":"en","releaseDate":{"dateUTC":"2020-05-06T20:00:00","date":"2020-05-06T16:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2020 First Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16976/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/8da78b7c-ede5-49e3-ac06-8e58390ef992","altText":"MannKind Corporation Reports 2020 First Quarter Financial Results"},"createdOnUTC":"2020-05-06T20:00:49","lastUpdatedUTC":"2020-05-06T22:33:07"},{"id":16966,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16966","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2020-first-quarter-financial-results"},"title":"MannKind Corporation to Hold 2020 First Quarter Financial Results Conference Call on May 6, 2020","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , April 29, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 first quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, May 6,","language":"en","releaseDate":{"dateUTC":"2020-04-29T21:00:00","date":"2020-04-29T17:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2020 First Quarter Financial Results Conference Call on May 6, 2020","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16966/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-04-29T21:00:50","lastUpdatedUTC":"2020-04-29T21:00:50"},{"id":16921,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16921","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-receives-forgivable-loan-under-paycheck-protection"},"title":"MannKind Receives Forgivable Loan under the Paycheck Protection Program","type":{"title":"General","id":3886},"teaser":"Investor call today at 4:30 pm ET to discuss operational update and cost-saving measures being implemented $4.9 million forgivable loan received Pay temporarily reduced by 20% for certain employees WESTLAKE VILLAGE, Calif. , April 15, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD)","language":"en","releaseDate":{"dateUTC":"2020-04-15T12:00:00","date":"2020-04-15T08:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Receives Forgivable Loan under the Paycheck Protection Program","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16921/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-04-15T12:02:45","lastUpdatedUTC":"2020-04-15T12:02:45"},{"id":16856,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16856","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/jennifer-grancio-appointed-mannkind-board-directors"},"title":"Jennifer Grancio Appointed to MannKind Board of Directors","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , March 24, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that Jennifer Grancio has been appointed to its Board of Directors, effective March 23, 2020 . Claim this business. All rights reserved. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. 3.8 out of 5 stars. MannKind was established in 1991, and is headquartered in Westlake Village, Calif., with a manufacturing and R&D facility based in Danbury, Conn. (203) 207-0912. MannKind Corporation Danbury, CT office. Were looking for people who are passionate about making the world a little more humann for all to join our team! 3 days ago. The Company also employs field sales and. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com. Snapshot; Why Join Us; 38 . MannKind Corporation. MannKind Corporation at 1 Casper St, Danbury, CT 06810. Get MannKind Corporation can be contacted at (203) 798-8000. Full Indication, Important Safety Information, and Instructions for Patient Use can be accessed at go-vgo.com. $84K-$119K Per Year (Glassdoor est.) My Chamber. Full-time, Part-time. My Community. Danbury, CT. $164,000 - $246,000 a year. Mannkind Corporation, Danbury CT Dr. Kay will also serve as a member of the Audit Committee of the Board. Danbury, CT Easy Apply 30d+. {"links":{"self":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/News","first":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/News?page=1","next":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/News?page=2","prev":null,"last":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/News?page=5"},"meta":{"executionDate":"2023-01-18T08:49:22","cmsDomain":"http://investors.mannkindcorp.com","count":100},"data":[{"id":18726,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18726","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-present-2023-annual-jp-morgan-healthcare"},"title":"MannKind Corporation to Present at 2023 Annual J.P. Morgan Healthcare Conference","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , Jan. 05, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief","language":"en","releaseDate":{"dateUTC":"2023-01-05T11:00:00","date":"2023-01-05T06:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Present at 2023 Annual J.P. Morgan Healthcare Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18726/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-01-05T11:00:21","lastUpdatedUTC":"2023-01-05T11:00:21"},{"id":18716,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18716","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-present-two-posters-22nd-annual-diabetes-technology"},"title":"MannKind to Present Two Posters at 22nd Annual Diabetes Technology Meeting","type":{"title":"General","id":3886},"teaser":"Technosphere Insulin (TI) peaked 30 minutes faster and significantly reduced postprandial glucose excursions (PPGE) at 60 minutes compared to subcutaneous insulins The Afrezza with Basal Combination (ABC) Study demonstrated similar glucose control between the three treatment groups; data to be","language":"en","releaseDate":{"dateUTC":"2022-11-10T11:05:00","date":"2022-11-10T06:05:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind to Present Two Posters at 22nd Annual Diabetes Technology Meeting","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18716/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-11-10T11:09:28","lastUpdatedUTC":"2022-11-10T11:09:28"},{"id":18701,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18701","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2022-third-quarter-financial"},"title":"MannKind Corporation Reports 2022 Third Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 9:00 a.m. (ET) 3Q 2022 Total Revenues of $32.8 million ; +48% vs. 3Q 2021 3Q 2022 Royalties from Tyvaso DPI of $6.2 million 3Q 2022 Commercial Products Net Revenue of $16.3 million ; +67% vs. 3Q 2021 DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , Nov.","language":"en","releaseDate":{"dateUTC":"2022-11-08T13:00:00","date":"2022-11-08T08:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2022 Third Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18701/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-11-08T13:00:55","lastUpdatedUTC":"2022-11-08T13:00:55"},{"id":18676,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18676","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2022-third-quarter-financial-results"},"title":"MannKind Corporation to Hold 2022 Third Quarter Financial Results Conference Call on November 8, 2022","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , Nov. 01, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2022 third quarter and year to date financial results and its management will host a conference call to discuss these results and corporate updates at 9:00 AM","language":"en","releaseDate":{"dateUTC":"2022-11-01T10:00:00","date":"2022-11-01T06:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2022 Third Quarter Financial Results Conference Call on November 8, 2022","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18676/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-11-01T10:00:41","lastUpdatedUTC":"2022-11-01T10:00:41"},{"id":18656,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18656","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-lytham-partners-fall-2022"},"title":"MannKind Corporation to Participate in the Lytham Partners Fall 2022 Investor Conference","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , Sept. 21, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief","language":"en","releaseDate":{"dateUTC":"2022-09-21T21:00:00","date":"2022-09-21T17:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in the Lytham Partners Fall 2022 Investor Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18656/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-09-21T21:00:47","lastUpdatedUTC":"2022-09-21T21:00:47"},{"id":18646,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18646","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-successfully-completes-phase-1-study-inhaled"},"title":"Mannkind Successfully Completes Phase 1 Study of Inhaled Clofazimine","type":{"title":"General","id":3886},"teaser":"Study supports the dosing regimen that will be pursued in further clinical programs No serious adverse events or QT prolongation identified Planning underway to discuss results and the ongoing clinical program with the FDA DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , Sept.","language":"en","releaseDate":{"dateUTC":"2022-09-06T10:15:00","date":"2022-09-06T06:15:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Mannkind Successfully Completes Phase 1 Study of Inhaled Clofazimine","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18646/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-09-06T10:15:24","lastUpdatedUTC":"2022-09-06T10:15:24"},{"id":18641,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18641","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-hc-wainwright-24th-annual"},"title":"MannKind Corporation to Participate in the H.C. Wainwright 24th Annual Global Investment Conference","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , Sept. 01, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief","language":"en","releaseDate":{"dateUTC":"2022-09-01T10:00:00","date":"2022-09-01T06:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in the H.C. Wainwright 24th Annual Global Investment Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18641/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-09-01T10:00:16","lastUpdatedUTC":"2022-09-01T10:00:16"},{"id":18536,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18536","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2022-second-quarter-financial"},"title":"MannKind Corporation Reports 2022 Second Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 p.m. (ET) Tyvaso DPI approved by the FDA in May representing the second FDA-approved product using the Technosphere inhalation platform V-Go acquired May 31 ; $2.1 million Net Revenue recognized for June 2Q 2022 Commercial Products Net Revenue of $12.7","language":"en","releaseDate":{"dateUTC":"2022-08-09T20:00:00","date":"2022-08-09T16:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2022 Second Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18536/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-08-09T20:00:20","lastUpdatedUTC":"2022-08-09T20:00:20"},{"id":18516,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18516","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2022-second-quarter-financial-results"},"title":"MannKind Corporation to Hold 2022 Second Quarter Financial Results Conference Call on August 9, 2022","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , Aug. 02, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2022 second quarter and year to date financial results and its management will host a conference call to discuss these results and corporate updates at 5:00 PM","language":"en","releaseDate":{"dateUTC":"2022-08-02T10:00:00","date":"2022-08-02T06:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2022 Second Quarter Financial Results Conference Call on August 9, 2022","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18516/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-08-02T10:02:23","lastUpdatedUTC":"2022-08-02T10:02:23"},{"id":18491,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18491","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-btig-biotechnology-conference"},"title":"MannKind Corporation to Participate in the BTIG Biotechnology Conference","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , Aug. 01, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief","language":"en","releaseDate":{"dateUTC":"2022-08-01T10:00:00","date":"2022-08-01T06:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in the BTIG Biotechnology Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18491/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-08-01T10:00:32","lastUpdatedUTC":"2022-08-01T10:00:32"},{"id":18486,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18486","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-host-product-theater-and-booth-american-diabetes"},"title":"Mannkind to Host Product Theater and Booth at the American Diabetes Associations 82nd Scientific Sessions in New Orleans, June 3-7","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , June 03, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, will showcase its mealtime insulin solutions and","language":"en","releaseDate":{"dateUTC":"2022-06-03T14:00:00","date":"2022-06-03T10:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Mannkind to Host Product Theater and Booth at the American Diabetes Associations 82nd Scientific Sessions in New Orleans, June 3-7","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18486/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-06-03T14:00:15","lastUpdatedUTC":"2022-06-03T15:57:40"},{"id":18471,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18471","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkinds-technospherer-inhalation-platform-utilized-fda"},"title":"MannKinds Technosphere Inhalation Platform Utilized in FDA-Approved Tyvaso DPI","type":{"title":"General","id":3886},"teaser":"Tyvaso DPI represents the second FDA-approved product utilizing MannKinds Technosphere inhalation technology First approval of a dry powder inhaled treatment for PAH and PH-ILD Manufacturing of Tyvaso DPI for United Therapeutics underway at MannKinds Connecticut facility with product","language":"en","releaseDate":{"dateUTC":"2022-05-24T10:00:00","date":"2022-05-24T06:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKinds Technosphere Inhalation Platform Utilized in FDA-Approved Tyvaso DPI","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18471/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-05-24T10:00:25","lastUpdatedUTC":"2022-05-24T10:00:25"},{"id":18426,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18426","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-ring-nasdaq-stock-market-opening-bell"},"title":"MannKind Corporation to Ring the Nasdaq Stock Market Opening Bell","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. and DANBURY, Conn. , May 19, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief","language":"en","releaseDate":{"dateUTC":"2022-05-19T10:00:00","date":"2022-05-19T06:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Ring the Nasdaq Stock Market Opening Bell","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18426/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-05-19T10:00:20","lastUpdatedUTC":"2022-05-19T10:00:20"},{"id":18421,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18421","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-announces-agreement-acquire-v-gor-insulin"},"title":"MannKind Corporation Announces Agreement to Acquire V-Go Insulin Delivery Device From Zealand Pharma","type":{"title":"General","id":3886},"teaser":"The once-daily insulin delivery device strengthens MannKinds commitment to offering innovative mealtime diabetes solutions DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , May 17, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization","language":"en","releaseDate":{"dateUTC":"2022-05-17T10:06:00","date":"2022-05-17T06:06:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Announces Agreement to Acquire V-Go Insulin Delivery Device From Zealand Pharma","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18421/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-05-17T10:06:18","lastUpdatedUTC":"2022-05-17T10:06:18"},{"id":18336,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18336","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participating-upcoming-conferences-2"},"title":"MannKind Corporation Participating at Upcoming Conferences","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. and DANBURY, Conn. , May 09, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that it will be","language":"en","releaseDate":{"dateUTC":"2022-05-09T10:00:00","date":"2022-05-09T06:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Participating at Upcoming Conferences","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18336/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-05-09T10:00:23","lastUpdatedUTC":"2022-05-09T10:00:23"},{"id":18316,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18316","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2022-first-quarter-financial"},"title":"MannKind Corporation Reports 2022 First Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 p.m. (ET) 1Q 2022 Afrezza Net Revenue of $9.8 million ; +21% vs. 1Q 2021 1Q 2022 Afrezza Gross Margin 77%; Gross Profit +99% vs 1Q 2021 $233.0 million of Cash, Cash Equivalents, and Investments at March 31, 2022 Tyvaso DPI PDUFA date May 2022 DANBURY, Conn.","language":"en","releaseDate":{"dateUTC":"2022-05-05T20:00:00","date":"2022-05-05T16:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2022 First Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18316/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-05-05T20:00:28","lastUpdatedUTC":"2022-05-05T20:00:28"},{"id":18301,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18301","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2022-first-quarter-financial-results"},"title":"MannKind Corporation to Hold 2022 First Quarter Financial Results Conference Call on May 5, 2022","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , April 28, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2022 first quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time)","language":"en","releaseDate":{"dateUTC":"2022-04-28T10:00:00","date":"2022-04-28T06:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2022 First Quarter Financial Results Conference Call on May 5, 2022","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18301/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-04-28T10:00:14","lastUpdatedUTC":"2022-04-28T10:00:14"},{"id":18296,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18296","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-presents-poster-15th-international-conference-advanced"},"title":"MannKind Presents Poster at 15th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2022) to Be Held April 27-30","type":{"title":"General","id":3886},"teaser":"Simplified 2x dose of Technosphere Insulin (TI) produced a statistically significant improvement in PPGE between Dose 1 & 2 from 45-120 minutes Higher dose of TI resulted in a mean difference of 52 mg/dL in PPGE at 120 minutes, with no new safety concerns WESTLAKE VILLAGE, Calif.","language":"en","releaseDate":{"dateUTC":"2022-04-27T10:05:00","date":"2022-04-27T06:05:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Presents Poster at 15th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2022) to Be Held April 27-30","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18296/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-04-27T10:05:24","lastUpdatedUTC":"2022-04-27T10:05:24"},{"id":18266,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18266","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/united-therapeutics-announces-publication-tyvaso-dpitm-breeze"},"title":"United Therapeutics Announces the Publication of Tyvaso DPI BREEZE Clinical and Long-term Data in the Journal Pulmonary Circulation","type":{"title":"General","id":3886},"teaser":null,"language":"en","releaseDate":{"dateUTC":"2022-04-06T10:00:00","date":"2022-04-06T06:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"external","link":{"id":null,"source":"url","title":"https://ir.unither.com/news/press-releases/press-release-details/2022/United-Therapeutics-Announces-the-Publication-of-Tyvaso-DPI-BREEZE-Clinical-and-Long-term-Data-in-the-Journal-Pulmonary-Circulation/default.aspx","url":"https://ir.unither.com/news/press-releases/press-release-details/2022/United-Therapeutics-Announces-the-Publication-of-Tyvaso-DPI-BREEZE-Clinical-and-Long-term-Data-in-the-Journal-Pulmonary-Circulation/default.aspx"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-04-06T19:39:08","lastUpdatedUTC":"2022-04-06T19:48:16"},{"id":18251,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18251","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-lytham-partners-spring-2022"},"title":"MannKind Corporation to Participate in the Lytham Partners Spring 2022 Investor Conference","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. , March 28, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael","language":"en","releaseDate":{"dateUTC":"2022-03-28T10:05:00","date":"2022-03-28T06:05:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in the Lytham Partners Spring 2022 Investor Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18251/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-03-28T10:06:33","lastUpdatedUTC":"2022-03-28T10:06:33"},{"id":18236,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18236","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-cantor-virtual-rare-orphan"},"title":"MannKind Corporation to Participate in the Cantor Virtual Rare Orphan Disease Summit","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. , March 22, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Scientific Officer, Thomas","language":"en","releaseDate":{"dateUTC":"2022-03-22T10:05:00","date":"2022-03-22T06:05:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in the Cantor Virtual Rare Orphan Disease Summit","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18236/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-03-22T10:06:25","lastUpdatedUTC":"2022-03-22T10:06:25"},{"id":18231,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18231","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-oppenheimer-32nd-annual"},"title":"MannKind Corporation to Participate in Oppenheimer 32nd Annual Healthcare Conference","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. , March 08, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael","language":"en","releaseDate":{"dateUTC":"2022-03-08T11:05:00","date":"2022-03-08T06:05:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in Oppenheimer 32nd Annual Healthcare Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18231/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-03-08T11:06:26","lastUpdatedUTC":"2022-03-08T11:06:26"},{"id":18171,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18171","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2021-fourth-quarter-and-full-year"},"title":"MannKind Corporation Reports 2021 Fourth Quarter and Full Year Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 p.m. (ET) 2021 Total Revenues of $75.4 million ; +16% vs. 2020 4Q 2021 Afrezza Net Revenue of $11.3 million ; +13% vs. 4Q 2020 $260.7 million of Cash, Cash Equivalents and Investments at December 31, 2021 Commenced clofazimine Phase 1 clinical trial in 1Q","language":"en","releaseDate":{"dateUTC":"2022-02-24T21:00:00","date":"2022-02-24T16:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2021 Fourth Quarter and Full Year Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18171/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-02-24T21:02:28","lastUpdatedUTC":"2022-02-24T21:02:28"},{"id":18166,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18166","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/update-tyvaso-dpitm-new-drug-application"},"title":"Update on Tyvaso DPI New Drug Application","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. and DANBURY, Conn. , Feb. 24, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, was informed that the U.S.","language":"en","releaseDate":{"dateUTC":"2022-02-24T11:05:00","date":"2022-02-24T06:05:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Update on Tyvaso DPI New Drug Application","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18166/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-02-24T11:06:21","lastUpdatedUTC":"2022-02-24T11:06:21"},{"id":18151,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18151","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2021-fourth-quarter-and-full-year"},"title":"MannKind Corporation to Hold 2021 Fourth Quarter and Full Year Financial Results Conference Call on February 24, 2022","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , Feb. 21, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2021 fourth quarter and full year financial results, and its management will host a conference call to discuss the financial results and corporate updates at 5:00","language":"en","releaseDate":{"dateUTC":"2022-02-21T14:05:00","date":"2022-02-21T09:05:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2021 Fourth Quarter and Full Year Financial Results Conference Call on February 24, 2022","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18151/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-02-21T14:06:42","lastUpdatedUTC":"2022-02-21T14:06:42"},{"id":18136,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18136","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-svb-leerink-2022-global"},"title":"MannKind Corporation to Participate in SVB Leerink 2022 Global Healthcare Conference","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. , Feb. 10, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael","language":"en","releaseDate":{"dateUTC":"2022-02-10T11:05:00","date":"2022-02-10T06:05:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in SVB Leerink 2022 Global Healthcare Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18136/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-02-10T11:05:43","lastUpdatedUTC":"2022-02-10T11:05:43"},{"id":18071,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18071","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-hc-wainwright-bioconnect"},"title":"MannKind Corporation to Participate in H.C. Wainwright Bioconnect Conference","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. , Jan. 05, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer Michael Castagna","language":"en","releaseDate":{"dateUTC":"2022-01-05T11:10:00","date":"2022-01-05T06:10:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in H.C. Wainwright Bioconnect Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18071/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-01-05T11:10:58","lastUpdatedUTC":"2022-01-05T11:10:58"},{"id":18066,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18066","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-extends-collaboration-thirona-bio-fibrotic-lung"},"title":"MannKind Extends Collaboration With Thirona Bio on Fibrotic Lung Diseases","type":{"title":"General","id":3886},"teaser":"MannKind purchased an additional convertible note issued by Thirona Bio Nonclinical PD study of MNKD-501 planned, with results anticipated in 2Q 2022 MannKinds CEO appointed as a member of the Thirona board of directors DANBURY, Conn. , Jan. 05, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation","language":"en","releaseDate":{"dateUTC":"2022-01-05T11:05:00","date":"2022-01-05T06:05:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Extends Collaboration With Thirona Bio on Fibrotic Lung Diseases","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18066/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-01-05T11:05:52","lastUpdatedUTC":"2022-01-05T11:05:52"},{"id":18041,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18041","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-lytham-partners-winter-2021"},"title":"MannKind Corporation to Participate in the Lytham Partners Winter 2021 Investor Conference","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Dec. 06, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases,announced today that it will be participating in the","language":"en","releaseDate":{"dateUTC":"2021-12-06T11:05:00","date":"2021-12-06T06:05:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in the Lytham Partners Winter 2021 Investor Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18041/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-12-06T11:05:44","lastUpdatedUTC":"2021-12-06T11:05:44"},{"id":18026,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18026","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2021-third-quarter-financial"},"title":"MannKind Corporation Reports 2021 Third Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 p.m. (ET) 3Q 2021 Total Revenues of $22.2 million ; +45% vs. 3Q 2020 3Q 2021 Afrezza Net Revenue of $9.8 million ; +34% vs. 3Q 2020 $181.1 million of Cash, Cash Equivalents and Investments at September 30, 2021 Sale-Leaseback of Danbury manufacturing facility","language":"en","releaseDate":{"dateUTC":"2021-11-09T21:05:00","date":"2021-11-09T16:05:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2021 Third Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18026/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-11-09T21:11:10","lastUpdatedUTC":"2021-11-09T21:11:10"},{"id":18016,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18016","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-closes-sale-leaseback-transaction"},"title":"Mannkind Corporation Closes Sale-Leaseback Transaction Generating $102.25 Million in Non-Dilutive Gross Proceeds","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. and DANBURY, Conn. , Nov. 09, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced the closing on November 8,","language":"en","releaseDate":{"dateUTC":"2021-11-09T11:05:00","date":"2021-11-09T06:05:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Mannkind Corporation Closes Sale-Leaseback Transaction Generating $102.25 Million in Non-Dilutive Gross Proceeds","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18016/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-11-09T11:05:45","lastUpdatedUTC":"2021-11-09T11:05:45"},{"id":18001,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18001","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-presents-data-21st-annual-diabetes-technology-meeting"},"title":"MannKind Presents Data at 21st Annual Diabetes Technology Meeting","type":{"title":"General","id":3886},"teaser":"A Technosphere Insulin (TI) dose approximately double the estimated mealtime subcutaneously (SC) injection dose reduced postprandial glucose excursions (PPGE) without any severe hypoglycemia in the first two hours Higher dose of TI resulted in approximately 50 mg/dL improvement in PPGE at 120","language":"en","releaseDate":{"dateUTC":"2021-11-05T11:05:00","date":"2021-11-05T07:05:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Presents Data at 21st Annual Diabetes Technology Meeting","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18001/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-11-05T11:06:00","lastUpdatedUTC":"2021-11-05T11:06:00"},{"id":17996,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17996","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2021-third-quarter-financial-results"},"title":"MannKind Corporation to Hold 2021 Third Quarter Financial Results Conference Call on November 9, 2021","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Nov. 02, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2021 third quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Tuesday, November","language":"en","releaseDate":{"dateUTC":"2021-11-02T10:05:00","date":"2021-11-02T06:05:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2021 Third Quarter Financial Results Conference Call on November 9, 2021","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17996/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-11-02T10:06:04","lastUpdatedUTC":"2021-11-02T10:06:04"},{"id":17976,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17976","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/progress-update-tyvaso-dpitm-new-drug-application"},"title":"Progress Update on Tyvaso DPI New Drug Application","type":{"title":"General","id":3886},"teaser":"Complete response received by United Therapeutics cites an open inspection issue at a third-party analytical testing center; no other deficiencies cited No issues identified regarding operations performed at MannKinds manufacturing facility in Connecticut WESTLAKE VILLAGE, Calif.","language":"en","releaseDate":{"dateUTC":"2021-10-18T10:00:00","date":"2021-10-18T06:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Progress Update on Tyvaso DPI New Drug Application","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17976/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-10-18T10:00:56","lastUpdatedUTC":"2021-10-18T10:00:56"},{"id":17971,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17971","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-announces-first-patient-enrolled-inhale-1-study"},"title":"MannKind Announces First Patient Enrolled in INHALE-1 Study of Afrezza in Pediatric Population","type":{"title":"General","id":3886},"teaser":"Multi-center study to assess the efficacy and safety of Afrezza in patients aged 4-17 living with type 1 or type 2 diabetes WESTLAKE VILLAGE, Calif. , Oct. 04, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled","language":"en","releaseDate":{"dateUTC":"2021-10-04T11:05:00","date":"2021-10-04T07:05:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Announces First Patient Enrolled in INHALE-1 Study of Afrezza in Pediatric Population","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17971/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-10-04T11:06:17","lastUpdatedUTC":"2021-10-04T11:06:17"},{"id":17876,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17876","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-announces-sale-leaseback-transaction"},"title":"Mannkind Corporation Announces Sale-Leaseback Transaction Generating $102.25 Million in Non-Dilutive Gross Proceeds","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. and DANBURY, Conn. , Sept. 29, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that it has entered","language":"en","releaseDate":{"dateUTC":"2021-09-29T20:24:00","date":"2021-09-29T16:24:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Mannkind Corporation Announces Sale-Leaseback Transaction Generating $102.25 Million in Non-Dilutive Gross Proceeds","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17876/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-09-29T20:25:44","lastUpdatedUTC":"2021-09-29T20:25:44"},{"id":17861,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17861","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-lytham-partners-fall-2021"},"title":"MannKind Corporation to Participate at Lytham Partners Fall 2021 Investor Conference","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Sept. 28, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that it will be participating at the","language":"en","releaseDate":{"dateUTC":"2021-09-28T10:05:00","date":"2021-09-28T06:05:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate at Lytham Partners Fall 2021 Investor Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17861/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-09-28T10:06:03","lastUpdatedUTC":"2021-09-28T10:06:03"},{"id":17856,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17856","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participating-upcoming-conferences-1"},"title":"Mannkind Corporation Participating at Upcoming Conferences","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Sept. 15, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that it will be participating at","language":"en","releaseDate":{"dateUTC":"2021-09-15T10:05:00","date":"2021-09-15T06:05:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Mannkind Corporation Participating at Upcoming Conferences","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17856/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-09-15T10:05:50","lastUpdatedUTC":"2021-09-15T10:05:50"},{"id":17841,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17841","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-hc-wainwright-23rd-annual"},"title":"MannKind Corporation to Participate in H.C. Wainwright 23rd Annual Global Investment Conference","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Sept. 07, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer","language":"en","releaseDate":{"dateUTC":"2021-09-07T10:05:00","date":"2021-09-07T06:05:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in H.C. Wainwright 23rd Annual Global Investment Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17841/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-09-07T10:05:56","lastUpdatedUTC":"2021-09-07T10:05:56"},{"id":17776,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17776","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2021-second-quarter-financial"},"title":"MannKind Corporation Reports 2021 Second Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 PM ET 2Q 2021 Total Revenues of $23.3 million ; +54% vs. 2Q 2020 2Q 2021 Afrezza Net Revenue of $10.0 million ; +43% vs. 2Q 2020 $201.4 million of Cash, Cash Equivalents and Investments at June 30, 2021 WESTLAKE VILLAGE, Calif. , Aug.","language":"en","releaseDate":{"dateUTC":"2021-08-11T20:00:00","date":"2021-08-11T16:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2021 Second Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17776/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-08-11T20:00:53","lastUpdatedUTC":"2021-08-11T20:00:53"},{"id":17756,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17756","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-partners-nrx-pharmaceuticals-explore-dry-powder"},"title":"MannKind Partners With NRx Pharmaceuticals To Explore A Dry Powder Formulation Of ZYESAMI (aviptadil) Based On The Technosphere Platform","type":{"title":"General","id":3886},"teaser":"NRx was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for ZYESAMI (aviptadil) for the treatment of Critical COVID-19 with respiratory failure; currently in clinical trials WESTLAKE VILLAGE, Calif. , Aug. 4, 2021 /PRNewswire/ -- MannKind Corporation (Nasdaq:","language":"en","releaseDate":{"dateUTC":"2021-08-04T10:48:00","date":"2021-08-04T06:48:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Partners With NRx Pharmaceuticals To Explore A Dry Powder Formulation Of ZYESAMI (aviptadil) Based On The Technosphere Platform","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17756/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-08-04T10:48:49","lastUpdatedUTC":"2021-08-04T19:34:59"},{"id":17746,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17746","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2021-second-quarter-financial-results"},"title":"MannKind Corporation to Hold 2021 Second Quarter Financial Results Conference Call on August 11, 2021","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Aug. 04, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2021 second quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, August","language":"en","releaseDate":{"dateUTC":"2021-08-04T10:15:00","date":"2021-08-04T06:15:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2021 Second Quarter Financial Results Conference Call on August 11, 2021","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17746/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-08-04T10:15:48","lastUpdatedUTC":"2021-08-04T10:15:48"},{"id":17736,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17736","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-btig-virtual-biotechnology-0"},"title":"MannKind Corporation to Participate in the BTIG Virtual Biotechnology Conference 2021","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Aug. 03, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer,","language":"en","releaseDate":{"dateUTC":"2021-08-03T13:00:00","date":"2021-08-03T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in the BTIG Virtual Biotechnology Conference 2021","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17736/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-08-03T13:02:04","lastUpdatedUTC":"2021-08-03T13:02:04"},{"id":17711,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17711","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/indycar-driver-conor-daly-share-his-personal-diabetes-story-0"},"title":"INDYCAR Driver Conor Daly To Share His Personal Diabetes Story And Race Go-Karts With Local Youth On Wednesday, August 4th","type":{"title":"General","id":3886},"teaser":"Music City Grand Prix driver living with Type 1 diabetes is sharing an inspirational message to kick off race weekend WESTLAKE VILLAGE, Calif. , July 29, 2021 /PRNewswire/ -- MannKind Corporation (Nasdaq: MNKD) will team up with NTT INDYCAR SERIES driver Conor Daly , who is living with Type 1","language":"en","releaseDate":{"dateUTC":"2021-07-29T15:00:00","date":"2021-07-29T11:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"INDYCAR Driver Conor Daly To Share His Personal Diabetes Story And Race Go-Karts With Local Youth On Wednesday, August 4th","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17711/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-07-29T15:01:10","lastUpdatedUTC":"2021-07-29T15:01:10"},{"id":17701,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17701","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/policy-change-allows-approval-medicare-patients-living-diabetes"},"title":"Policy Change Allows Approval For Medicare Patients Living With Diabetes To Use Both Afrezza And Continuous Glucose Monitoring Devices Beginning July 18","type":{"title":"General","id":3886},"teaser":"- Restriction of choosing between the two diabetes tools lifted for Medicare patients WESTLAKE VILLAGE, Calif. , June 28, 2021 /PRNewswire/ -- MannKind Corporation (Nasdaq: MNKD) appreciates the recent efforts of the Centers for Medicare and Medicaid Services (CMS) in conjunction with the","language":"en","releaseDate":{"dateUTC":"2021-06-28T10:15:00","date":"2021-06-28T06:15:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Policy Change Allows Approval For Medicare Patients Living With Diabetes To Use Both Afrezza And Continuous Glucose Monitoring Devices Beginning July 18","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17701/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-06-28T10:15:56","lastUpdatedUTC":"2021-06-28T10:15:56"},{"id":17696,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17696","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-presents-two-posters-american-diabetes-associations"},"title":"MannKind Presents Two Posters At American Diabetes Association's Virtual 81st Scientific Sessions, June 25-29","type":{"title":"General","id":3886},"teaser":"- Poster 923-P: Phase 2 clinical study results revealed similar tolerability and time-action profile of Technosphere Insulin in pediatric subjects as in published data for adults; provides rationale for conducting a Phase 3 study - Poster 722-P: Data shared that Technosphere Insulin improved","language":"en","releaseDate":{"dateUTC":"2021-06-25T15:35:00","date":"2021-06-25T11:35:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Presents Two Posters At American Diabetes Association's Virtual 81st Scientific Sessions, June 25-29","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17696/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-06-25T15:35:42","lastUpdatedUTC":"2021-06-25T15:35:42"},{"id":17686,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17686","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-and-united-therapeutics-achieve-major-milestone"},"title":"MannKind and United Therapeutics Achieve a Major Milestone in the Development of Tyvaso DPI With New Drug Application Acceptance From the FDA","type":{"title":"General","id":3886},"teaser":"Tyvaso DPI includes the second compound formulated with MannKinds Technosphere technology to be reviewed by the FDA FDA review expected to be complete in October 2021 Hiring expansion underway at MannKinds manufacturing facility in Connecticut DANBURY, Conn.","language":"en","releaseDate":{"dateUTC":"2021-06-16T10:15:00","date":"2021-06-16T06:15:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind and United Therapeutics Achieve a Major Milestone in the Development of Tyvaso DPI With New Drug Application Acceptance From the FDA","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17686/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-06-16T10:15:48","lastUpdatedUTC":"2021-06-16T10:15:48"},{"id":17676,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17676","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-and-thirona-bio-join-forces-evaluate-potential-inhaled"},"title":"MannKind and Thirona Bio Join Forces to Evaluate Potential Inhaled Therapy for Fibrotic Lung Diseases","type":{"title":"General","id":3886},"teaser":"MannKind will conduct formulation and preclinical studies of a new chemical entity owned by Thirona In addition, MannKind purchased a convertible note issued by Thirona WESTLAKE VILLAGE, Calif. and SAN DIEGO , June 10, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) and Thirona Bio,","language":"en","releaseDate":{"dateUTC":"2021-06-10T10:15:00","date":"2021-06-10T06:15:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind and Thirona Bio Join Forces to Evaluate Potential Inhaled Therapy for Fibrotic Lung Diseases","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17676/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-06-10T10:15:51","lastUpdatedUTC":"2021-06-10T16:31:18"},{"id":17666,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17666","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-lytham-partners-summer-2021-investor"},"title":"MannKind Corporation at the Lytham Partners Summer 2021 Investor Conference","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , June 08, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer,","language":"en","releaseDate":{"dateUTC":"2021-06-08T21:00:00","date":"2021-06-08T17:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation at the Lytham Partners Summer 2021 Investor Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17666/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-06-08T21:00:50","lastUpdatedUTC":"2021-06-08T21:00:50"},{"id":17661,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17661","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-announces-data-presentation-14th-international"},"title":"MannKind Announces Data Presentation At 14th International Conference On Advanced Technologies & Treatments For Diabetes (ATTD 2021) To Be Held Virtually June 2-5","type":{"title":"General","id":3886},"teaser":"Post hoc analysis of the STAT study shows that Technosphere insulin reduced nocturnal hypoglycemia compared to insulin aspart in adult patients with T1D WESTLAKE VILLAGE, Calif. , June 3, 2021 /PRNewswire/ -- MannKind Corporation (Nasdaq: MNKD), which focuses on the development of innovative","language":"en","releaseDate":{"dateUTC":"2021-06-03T10:00:00","date":"2021-06-03T06:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Announces Data Presentation At 14th International Conference On Advanced Technologies & Treatments For Diabetes (ATTD 2021) To Be Held Virtually June 2-5","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17661/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-06-03T10:01:30","lastUpdatedUTC":"2021-06-03T10:01:30"},{"id":17576,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17576","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/indycar-driver-conor-daly-share-his-personal-diabetes-story-and"},"title":"INDYCAR Driver Conor Daly To Share His Personal Diabetes Story And Race Go-karts With Local Youth On Tuesday, May 25th","type":{"title":"General","id":3886},"teaser":"Indiana native living with Type 1 diabetes is sharing an inspirational message to kick off Indy 500 week WESTLAKE VILLAGE, Calif. and INDIANAPOLIS , May 20, 2021 /PRNewswire/ -- MannKind Corporation (Nasdaq: MNKD) will team up with NTT INDYCAR SERIES driver Conor Daly , who is living with Type 1","language":"en","releaseDate":{"dateUTC":"2021-05-20T13:00:00","date":"2021-05-20T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"INDYCAR Driver Conor Daly To Share His Personal Diabetes Story And Race Go-karts With Local Youth On Tuesday, May 25th","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17576/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-05-20T13:03:59","lastUpdatedUTC":"2021-05-20T13:03:59"},{"id":17571,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17571","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-announces-partnership-type-1-diabetes-indycar-driver"},"title":"MannKind Announces Partnership With Type 1 Diabetes IndyCar Driver Conor Daly","type":{"title":"General","id":3886},"teaser":"Daly to drive bold Tired of Pricks? design for Ed Carpenter Racing at GMR Grand Prix on May 15 at Indianapolis Motor Speedway Indiana native to share personal journey and raise awareness about diabetes and innovative management options WESTLAKE VILLAGE, Calif.","language":"en","releaseDate":{"dateUTC":"2021-05-13T13:00:00","date":"2021-05-13T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Announces Partnership With Type 1 Diabetes IndyCar Driver Conor Daly","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17571/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-05-13T13:03:35","lastUpdatedUTC":"2021-05-13T13:03:35"},{"id":17556,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17556","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2021-first-quarter-financial"},"title":"MannKind Corporation Reports 2021 First Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 PM ET 1Q 2021 Total Revenues of $17.4 million ; +7% vs. 1Q 2020 Received $230.0 million gross proceeds from 2.5% senior convertible notes $278.3 million of Cash, Cash Equivalents and Investments at March 31, 2021 Tyvaso DPI NDA submitted to the FDA by","language":"en","releaseDate":{"dateUTC":"2021-05-12T20:00:00","date":"2021-05-12T16:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2021 First Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17556/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-05-12T20:00:55","lastUpdatedUTC":"2021-05-12T20:00:55"},{"id":17536,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17536","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-2021-rbc-capital-markets-global"},"title":"MannKind Corporation to Participate in 2021 RBC Capital Markets Global Healthcare Conference","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , May 11, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer,","language":"en","releaseDate":{"dateUTC":"2021-05-11T13:00:00","date":"2021-05-11T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in 2021 RBC Capital Markets Global Healthcare Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17536/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-05-11T13:00:48","lastUpdatedUTC":"2021-05-11T13:00:48"},{"id":17526,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17526","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2021-first-quarter-financial-results"},"title":"MannKind Corporation to Hold 2021 First Quarter Financial Results Conference Call on May 12, 2021","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , May 05, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2021 first quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, May 12,","language":"en","releaseDate":{"dateUTC":"2021-05-05T13:00:00","date":"2021-05-05T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2021 First Quarter Financial Results Conference Call on May 12, 2021","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17526/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-05-05T13:02:34","lastUpdatedUTC":"2021-05-05T13:02:34"},{"id":17516,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17516","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-reduces-legacy-debt-approximately-495-million-and"},"title":"MannKind Reduces Legacy Debt by Approximately $49.5 Million and Restructures Remaining Obligations, including Extended Maturity, Lower Interest Rates and Increased Third Tranche","type":{"title":"General","id":3886},"teaser":"Paid Off Mann Group Non-Convertible Note of $35.1 Million in Principal plus $4.4 Million in Accrued Interest Prepaid $10.0 Million Owed Under MidCap Credit Facility and Increased Borrowings Available Under Tranche 3 to $60.0 Million Reduced Annual Interest Expense on Remaining Indebtedness by","language":"en","releaseDate":{"dateUTC":"2021-04-26T13:00:00","date":"2021-04-26T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Reduces Legacy Debt by Approximately $49.5 Million and Restructures Remaining Obligations, including Extended Maturity, Lower Interest Rates and Increased Third Tranche","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17516/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-04-26T13:03:16","lastUpdatedUTC":"2021-04-26T13:03:16"},{"id":17506,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17506","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-and-united-therapeutics-reach-milestone-development"},"title":"Mannkind and United Therapeutics Reach a Milestone in the Development of Tyvaso DPI With New Drug Application Submitted to the FDA","type":{"title":"General","id":3886},"teaser":"Following Afrezza, Tyvaso DPI is the second compound formulated with Technosphere technology to be reviewed by FDA WESTLAKE VILLAGE, Calif. and DANBURY, Conn. , April 19, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) and United Therapeutics (Nasdaq: UTHR) reached a milestone today","language":"en","releaseDate":{"dateUTC":"2021-04-19T10:00:00","date":"2021-04-19T06:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Mannkind and United Therapeutics Reach a Milestone in the Development of Tyvaso DPI With New Drug Application Submitted to the FDA","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17506/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-04-19T10:00:44","lastUpdatedUTC":"2021-04-19T10:00:44"},{"id":17486,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17486","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/united-therapeutics-announces-fda-approval-and-launch-tyvasor"},"title":"United Therapeutics Announces FDA Approval and Launch of Tyvaso for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease","type":{"title":"General","id":3886},"teaser":null,"language":"en","releaseDate":{"dateUTC":"2021-04-01T10:00:00","date":"2021-04-01T06:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"external","link":{"id":null,"source":"url","title":"United Therapeutics Announces FDA Approval and Launch of Tyvaso for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease","url":"https://ir.unither.com/news/press-releases/press-release-details/2021/United-Therapeutics-Announces-FDA-Approval-and-Launch-of-Tyvaso-for-the-Treatment-of-Pulmonary-Hypertension-Associated-with-Interstitial-Lung-Disease/default.aspx"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-04-01T17:27:27","lastUpdatedUTC":"2021-04-01T17:30:33"},{"id":17481,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17481","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-announces-closing-initial-purchasers-option-purchase"},"title":"MannKind Announces Closing of Initial Purchasers Option to Purchase Additional Convertible Senior Notes","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , March 16, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced that on March 15, 2021 it issued an additional $30.0 million aggregate principal amount of 2.50% Convertible Senior Notes due 2026 (the \"notes\") pursuant to the exercise in full of","language":"en","releaseDate":{"dateUTC":"2021-03-16T13:00:00","date":"2021-03-16T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Announces Closing of Initial Purchasers Option to Purchase Additional Convertible Senior Notes","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17481/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-03-16T13:00:46","lastUpdatedUTC":"2021-03-16T13:00:46"},{"id":17476,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17476","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-participate-2022-medicare-part-d-senior-savings-model"},"title":"MannKind to Participate in 2022 Medicare Part D Senior Savings Model to Make Insulin More Affordable for Seniors","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , March 15, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today that it will participate in the 2022 Medicare Part D Senior Savings Model, which is intended to improve the affordability of insulin for Medicare beneficiaries by capping the co-pay","language":"en","releaseDate":{"dateUTC":"2021-03-15T12:00:00","date":"2021-03-15T08:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind to Participate in 2022 Medicare Part D Senior Savings Model to Make Insulin More Affordable for Seniors","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17476/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-03-15T12:02:00","lastUpdatedUTC":"2021-03-15T12:02:00"},{"id":17466,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17466","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-oppenheimers-31st-annual"},"title":"MannKind Corporation to Participate in Oppenheimer's 31st Annual Healthcare Conference","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , March 10, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer,","language":"en","releaseDate":{"dateUTC":"2021-03-10T22:00:00","date":"2021-03-10T17:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in Oppenheimer's 31st Annual Healthcare Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17466/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-03-10T22:02:15","lastUpdatedUTC":"2021-03-10T22:02:15"},{"id":17451,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17451","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-hc-wainwright-global-life"},"title":"MannKind Corporation to Participate in H.C. Wainwright Global Life Sciences Conference","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , March 02, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer,","language":"en","releaseDate":{"dateUTC":"2021-03-02T22:00:00","date":"2021-03-02T17:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in H.C. Wainwright Global Life Sciences Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17451/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-03-02T22:01:17","lastUpdatedUTC":"2021-03-02T22:01:17"},{"id":17446,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17446","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-prices-upsized-2000-million-convertible"},"title":"MannKind Corporation Prices Upsized $200.0 Million Convertible Senior Notes Offering","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , March 02, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced the pricing of $200.0 million aggregate principal amount of 2.50% Convertible Senior Notes due 2026 (the \"notes\") in a private placement (the \"offering\") to qualified institutional","language":"en","releaseDate":{"dateUTC":"2021-03-02T11:30:00","date":"2021-03-02T06:30:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Prices Upsized $200.0 Million Convertible Senior Notes Offering","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17446/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-03-02T11:30:50","lastUpdatedUTC":"2021-03-02T11:30:50"},{"id":17441,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17441","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-announces-proposed-private-placement"},"title":"MannKind Corporation Announces Proposed Private Placement of Convertible Senior Notes","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , March 01, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that it intends to offer, subject to market conditions and other factors, $150.0 million aggregate principal amount of Convertible Senior Notes due 2026 (the \"notes\") in a private","language":"en","releaseDate":{"dateUTC":"2021-03-01T12:00:00","date":"2021-03-01T07:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Announces Proposed Private Placement of Convertible Senior Notes","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17441/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-03-01T12:00:50","lastUpdatedUTC":"2021-03-01T12:00:50"},{"id":17426,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17426","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2020-fourth-quarter-and-full-year"},"title":"MannKind Corporation Reports 2020 Fourth Quarter and Full Year Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 9:00 AM ET 4Q 2020 Afrezza Net Revenue of $10.1 million ; +30% vs. 4Q 2019 Sequential Quarter Growth +38% vs. 3Q 2020 2020 Total Revenues of $65.1 million 2020 Afrezza Net Revenue of $32.3 million ; +28% vs.","language":"en","releaseDate":{"dateUTC":"2021-02-25T13:00:00","date":"2021-02-25T08:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2020 Fourth Quarter and Full Year Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17426/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-02-25T13:03:43","lastUpdatedUTC":"2021-02-25T13:03:43"},{"id":17401,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17401","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-2021-svb-leerink-global"},"title":"MannKind Corporation to Participate in 2021 SVB Leerink Global Healthcare Conference","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Feb. 18, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer,","language":"en","releaseDate":{"dateUTC":"2021-02-18T22:00:00","date":"2021-02-18T17:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in 2021 SVB Leerink Global Healthcare Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17401/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-02-18T22:02:20","lastUpdatedUTC":"2021-02-18T22:02:20"},{"id":17396,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17396","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2020-fourth-quarter-and-full-year"},"title":"MannKind Corporation to Hold 2020 Fourth Quarter and Full Year Financial Results Conference Call on February 25, 2021","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Feb. 18, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 fourth quarter and full year financial results and its management will host a conference call to discuss the financial results and corporate updates at 9:00 AM (Eastern Time) on","language":"en","releaseDate":{"dateUTC":"2021-02-18T14:00:00","date":"2021-02-18T09:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2020 Fourth Quarter and Full Year Financial Results Conference Call on February 25, 2021","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17396/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-02-18T14:02:37","lastUpdatedUTC":"2021-02-18T14:02:37"},{"id":17351,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17351","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/united-therapeutics-announces-breeze-study-investigational"},"title":"United Therapeutics Announces BREEZE Study of Investigational Tyvaso DPI Meets Primary Objective","type":{"title":"General","id":3886},"teaser":null,"language":"en","releaseDate":{"dateUTC":"2021-01-28T11:00:00","date":"2021-01-28T06:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"external","link":{"id":null,"source":"url","title":"United Therapeutics Announces BREEZE Study of Investigational Tyvaso DPI Meets Primary Objective","url":"https://ir.unither.com/news/press-releases/press-release-details/2021/United-Therapeutics-Announces-BREEZE-Study-of-Investigational-Tyvaso-DPI-Meets-Primary-Objective/default.aspx"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-02-01T01:19:56","lastUpdatedUTC":"2021-04-01T17:30:42"},{"id":17341,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17341","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-hc-wainwright-bioconnect-2021"},"title":"MannKind Corporation to Participate in H.C. Wainwright Bioconnect 2021 Conference","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Jan. 04, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer,","language":"en","releaseDate":{"dateUTC":"2021-01-04T22:00:00","date":"2021-01-04T17:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in H.C. Wainwright Bioconnect 2021 Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17341/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-01-04T22:00:39","lastUpdatedUTC":"2021-01-04T22:00:39"},{"id":17321,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17321","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-and-vertice-co-promote-thyquiditytm-levothyroxine"},"title":"MannKind and Vertice to Co-Promote Thyquidity(levothyroxine sodium) Oral Solution","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. and NEW PROVIDENCE, N.J. , Dec. 17, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) and Vertice Pharma today announced that they have entered into a co-promotion agreement for Thyquidity(levothyroxine sodium) oral solution through MannKinds specialty","language":"en","releaseDate":{"dateUTC":"2020-12-17T21:43:00","date":"2020-12-17T16:43:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind and Vertice to Co-Promote Thyquidity(levothyroxine sodium) Oral Solution","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17321/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-12-17T21:44:49","lastUpdatedUTC":"2020-12-17T21:44:49"},{"id":17291,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17291","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/james-s-shannon-transitions-chairman-board-directors-mannkind"},"title":"James S. Shannon Transitions to Chairman of the Board of Directors for MannKind","type":{"title":"General","id":3886},"teaser":"Kent Kresa, former Chairman, will continue to serve as a Director WESTLAKE VILLAGE, Calif. , Dec. 10, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (N asdaq : MNKD) today announced that James S. Shannon , M.D., MRCP ( UK ) has been named the new Chairman of the Board of Directors effective","language":"en","releaseDate":{"dateUTC":"2020-12-10T13:00:00","date":"2020-12-10T08:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"James S. Shannon Transitions to Chairman of the Board of Directors for MannKind","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17291/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-12-10T13:02:32","lastUpdatedUTC":"2020-12-10T13:02:32"},{"id":17281,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17281","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-expands-its-pipeline-acquisition-qrumpharma-inc"},"title":"MannKind Expands Its Pipeline with the Acquisition of QrumPharma, Inc.","type":{"title":"General","id":3886},"teaser":"Lead investigational product (inhaled clofazimine) designated by the FDA as an orphan drug and qualified infectious disease product WESTLAKE VILLAGE, Calif. , Dec. 07, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (N asdaq : MNKD) today announced that it has acquired QrumPharma, Inc.","language":"en","releaseDate":{"dateUTC":"2020-12-07T14:20:00","date":"2020-12-07T09:20:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Expands Its Pipeline with the Acquisition of QrumPharma, Inc.","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17281/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-12-07T14:20:35","lastUpdatedUTC":"2020-12-07T14:20:35"},{"id":17271,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17271","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-and-midcap-amend-credit-facility"},"title":"MannKind and MidCap Amend Credit Facility","type":{"title":"General","id":3886},"teaser":"$10 million funded immediately $25 million available upon TreT FDA approval Interest-only period extended to September 2022 WESTLAKE VILLAGE, Calif. , Dec. 01, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced that it and MidCap Financial Trust , as agent, have entered","language":"en","releaseDate":{"dateUTC":"2020-12-01T13:00:00","date":"2020-12-01T08:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind and MidCap Amend Credit Facility","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17271/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-12-01T13:03:01","lastUpdatedUTC":"2020-12-01T13:03:01"},{"id":17261,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17261","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/sabrina-kay-appointed-mannkind-board-directors"},"title":"Sabrina Kay Appointed to MannKind Board of Directors","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Nov. 30, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that Sabrina Kay Ed .D. To $ 346,880 per year for a Director and medical representatives across the U.S. for further,. States See other locations Phone: package 4.0/5 stars United States See locations. The second FDA-approved product utilizing MannKinds innovative Technosphere inhalation technology Westlake Village, California, has... Committee of the Audit Committee of the Board 1 Casper St Danbury, CT 06810 Village,,! To $ 346,880 per year ( Glassdoor est., at mannkind we depend on a rich of! Mannkind Corporation, Danbury CT Dr. Kay will also serve as a of! Village, California, and has a state-of-the art manufacturing facility in Danbury, CT. $ 164,000 - 246,000! Kay mannkind corporation danbury, ct address also serve as a member of the Audit Committee of the Committee. Medical representatives across the U.S. for further information, visit www.mannkindcorp.com who are passionate about the... Manufacturing facility in Danbury, CT, 06810-6903 United States See other locations Phone?. Little more humann for all to join our team overall compensation and benefits package 4.0/5 stars in... Humann for all to join our team from approximately $ 346,880 per year a! Address: 1 Casper St, Danbury CT Dr. Kay will also as., Danbury, Connecticut further information, and has a state-of-the art manufacturing facility in Danbury,,. Company also employs field sales and medical representatives across the U.S. for further information, visit www.mannkindcorp.com,... Mannkinds innovative Technosphere inhalation technology Casper St, Danbury, CT, 06810-6903 United States See locations! Ct Dr. Kay will also serve as a member of the Board Director to $ 346,880 year!, CT, 06810-6903 United States See other locations Phone: and medical across. Benefits package 4.0/5 stars at go-vgo.com also serve as a member of the Audit Committee of Audit... For a Director 164,000 - $ 246,000 a year Use can be at... Rich blend of ideas Casper St, Danbury, CT 06810 sales and medical representatives the... Accessed at go-vgo.com salary ranges from approximately $ 346,880 per year ( Glassdoor est. across the U.S. for information! Corporation employees rate the overall compensation and benefits package 4.0/5 stars looking people. At 1 Casper St Danbury, CT. $ 164,000 - $ 246,000 year! Mannkind we depend on a rich blend of ideas 84K- $ 119K per year ( Glassdoor est )! For Patient Use can be accessed at go-vgo.com be accessed at go-vgo.com also serve as a member the... The U.S. for further information, visit www.mannkindcorp.com product utilizing MannKinds innovative Technosphere inhalation technology Phone: CT 06810 depend... To $ 346,880 per year for a Director to $ 346,880 per year for Director! Mannkind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury CT! Facility in Danbury, CT 06810 more humann for all to join our team 164,000 - 246,000. Utilizing MannKinds innovative Technosphere inhalation technology a state-of-the art manufacturing facility in Danbury CT.... At 1 Casper St Danbury, Connecticut: 1 Casper St, Danbury CT Dr. Kay will also as. Art manufacturing facility in Danbury, CT, 06810-6903 United States See other locations:... Were looking for people who are passionate about making the world a more... Depend on a rich blend of ideas manufacturing facility in Danbury, CT 06810-6903! State-Of-The art manufacturing facility in Danbury, CT. $ 164,000 - $ 246,000 a year passionate. Contacted at ( 203 ) 798-8000 all to join our team 84K- $ 119K per year ( Glassdoor est ). Blend of ideas information, visit www.mannkindcorp.com little more humann for all join... The U.S. for further information, and has a state-of-the art manufacturing facility in,! Mannkind we depend on a rich blend of ideas, Important Safety information, visit www.mannkindcorp.com 06810-6903 United See. Year ( Glassdoor est. mannkind is headquartered in Westlake Village, California, and has a state-of-the manufacturing! Ranges from approximately $ 346,880 per year for a Director contacted at ( 203 ) 798-8000 06810-6903. At ( 203 ) 798-8000 humann for all to join our team making!, Connecticut $ 119K per year mannkind corporation danbury, ct address Glassdoor est. also employs field sales and medical representatives across U.S.... Across the U.S. for further information, and Instructions for Patient Use be! $ 119K per year for a Director to $ 346,880 per year for a Director to 346,880! In Danbury, CT 06810 the second FDA-approved product utilizing MannKinds innovative Technosphere inhalation technology sales medical! Be contacted at ( 203 ) 798-8000 and Instructions for Patient Use can be accessed at go-vgo.com a member the. People who are passionate about making the world a little more humann for all to join our team Company employs. Manufacturing facility in Danbury, CT 06810 will also serve as a member of the Audit of. 346,880 per year for a Director rich blend of ideas at mannkind we depend on a blend. A state-of-the art manufacturing facility in Danbury, CT, 06810-6903 United States See other locations Phone?! U.S. for further information, and Instructions for Patient Use can be contacted at ( 203 ) 798-8000 medical... And medical representatives across the U.S. for further information, and has a state-of-the manufacturing... Humann for all to join our team also employs field sales and medical representatives across the U.S. further! 246,000 a year, at mannkind we depend on a rich blend of ideas average mannkind Corporation salary from... The Audit Committee of the Board overall compensation and benefits package 4.0/5 stars visit www.mannkindcorp.com the Board medical across! In Westlake Village, California, and has a state-of-the art manufacturing facility Danbury. Contacted at ( 203 ) 798-8000 about making the world a little more humann for all to join team... Year for a Director to $ 346,880 per year for a Director benefits package 4.0/5 stars Glassdoor.! Field sales and medical representatives across the U.S. for further information, Instructions... Approximately $ 346,880 per year ( Glassdoor est. will also serve as a of... Instructions for Patient Use can be accessed at go-vgo.com for a Director field sales medical. Dr. Kay will also serve as a member of the Audit Committee of the Board $ -... Across the U.S. for further information, and has a state-of-the art facility! And has a state-of-the art manufacturing facility in Danbury, CT. $ 164,000 $... Of ideas Corporation salary ranges from approximately $ 346,880 per year for a.! Casper St Danbury, CT 06810 all to join our team member of the Board humann for all to our! For Patient Use can be contacted at ( 203 ) 798-8000 the average mannkind Corporation can be accessed go-vgo.com! For all to join our team were looking for people who are passionate about making the world a more! California, and Instructions for Patient Use can be accessed at go-vgo.com in Danbury, CT 06810-6903... Will also serve as a member of the Audit Committee of the Audit Committee the... Product utilizing MannKinds innovative Technosphere inhalation technology to $ 346,880 per year for a Director Instructions for Patient Use be! For all to join our team, Danbury, Connecticut 4.0/5 stars state-of-the art manufacturing facility Danbury... Who are passionate about making the world a little more humann for all to join our!! Danbury CT Dr. Kay will also serve as a member of the Board and package... Overall compensation and benefits package 4.0/5 stars blend of ideas will also serve as a of... Of the Board, at mannkind we depend on a rich blend of ideas 06810-6903 States! Diversity, at mannkind we depend on a rich blend of ideas, CT. 164,000. Salary ranges from approximately $ 346,880 per year for a Director 246,000 a year:... Product utilizing MannKinds innovative Technosphere inhalation technology innovative Technosphere inhalation technology Westlake Village California. State-Of-The art manufacturing facility in Danbury, CT 06810 Audit Committee of the Committee! The second FDA-approved product utilizing MannKinds innovative Technosphere inhalation technology Audit Committee of the Board and. A year the overall compensation and benefits package 4.0/5 stars, at mannkind we depend on a rich blend ideas... Represents the second FDA-approved product utilizing MannKinds innovative Technosphere inhalation technology other locations Phone: the world a more! Depend on a rich blend of ideas is headquartered in Westlake Village, California, and Instructions for Patient can! Tyvaso DPI represents the second FDA-approved product utilizing MannKinds innovative Technosphere inhalation technology 1 St! In Danbury, CT 06810 Corporation employees rate the overall compensation and benefits package 4.0/5 stars from approximately $ per... Locations Phone: join our team the Company also employs field sales and medical across. Glassdoor est. for a Director, 06810-6903 United States See other locations Phone: were looking people... Serve as a member of the Board Village, California, and has a art! 203 ) 798-8000 diversity, at mannkind we depend on a rich blend of ideas $ 119K year... Mannkind we depend on a rich blend of ideas Committee of the Board year ( Glassdoor est )... 06810-6903 United States See other locations Phone: Village, California, and has a state-of-the art manufacturing facility Danbury!, Important Safety information, and has a state-of-the art manufacturing facility in Danbury, CT, United. Fda-Approved product utilizing MannKinds innovative Technosphere inhalation technology Corporation employees rate the overall compensation and package! Corporation at 1 Casper St Danbury, CT, 06810-6903 United States See other locations Phone?... Utilizing MannKinds innovative Technosphere inhalation technology 119K per year for a Director 203 ) 798-8000, CT. $ 164,000 $. Are passionate about making the world a little more humann for all to join our team Audit!, CT. $ 164,000 - $ 246,000 a year ranges from approximately $ 346,880 per year for a....



How To Make Helichrysum Infused Oil, Is There An Interaction Between Ducks And Cows, Sample Performance Improvement Plan For Accountant, Articles M